ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Recombinant Heparin: An Old Drug for the Modern World

B.E. Thacker1, K. Thorne1, C. Cartwright1, J. Park1, K. Glass1, A. Chea1, J.D. Esko2, W. Jeske3, J.M. Walenga3, C.A. Glass1

1TEGA Therapeutics, Inc., San Diego, United States, 2University of California, San Diego, La Jolla, United States, 3Loyola University Medical Center, Maywood, United States

Abstract Number: LPB0006

Meeting: ISTH 2021 Congress

Theme: Coagulation and Natural Anticoagulants » Coagulation Factors and Inhibitors

Background: Although most biologics are produced using recombinant technologies, heparin persists as a product purified from animal tissues. A cell based system for production of heparin would eliminate risk of supply shortage and contamination. While heparin is produced uniquely by mast cells, all mammalian cells produce heparan sulfate, a closely related and non-anticoagulant polysaccharide, in a shared biosynthetic pathway. Production of recombinant heparin in mammalian cells requires engineering the heparan sulfate biosynthetic pathway, which consists of more than 20 biosynthetic enzymes, to produce material with anticoagulant activity.

Aims: This work is focused on engineering mammalian cell lines and bioprocess methods to produce recombinant heparin.

Methods: The heparan sulfate biosynthetic pathway of mastocytoma cells was genetically engineered to alter the expression of heparan sulfate sulfotransferases. The resulting cell lines were screened for production of anti-Xa activity. Heparan sulfate production from a candidate cell line in chemically defined medium was tested. The recombinant product was characterized structurally and in clotting and anti-protease assays.

Results: Overexpression of sulfotransferases in engineered mastocytoma cells produced heparan sulfate with anti-Xa (297 U/mg) and anti-IIa (311 U/mg) activity exceeding the USP requirement for unfractionated heparin despite having lower sulfate content. APTT activity was similar to unfractionated heparin. Chain length was longer than unfractionated heparin.

Conclusions: Genetic manipulation of the biosynthetic pathway yielded heparan sulfate with anticoagulant potency. These results demonstrate the feasibility of producing a substitute for unfractionated heparin from recombinant cell culture.

To cite this abstract in AMA style:

Thacker BE, Thorne K, Cartwright C, Park J, Glass K, Chea A, Esko JD, Jeske W, Walenga JM, Glass CA. Recombinant Heparin: An Old Drug for the Modern World [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/recombinant-heparin-an-old-drug-for-the-modern-world/. Accessed May 19, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/recombinant-heparin-an-old-drug-for-the-modern-world/

Simple Search

Supported By:

Bristol Myers Squibb and Pfizer

ISTH 2021 Congress site

Visit the official web site for the ISTH 2021 Virtual CongressĀ Ā»

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley